A Study of SRSD384 in Overweight or Obese Participants (NCT07557355) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
A Study of SRSD384 in Overweight or Obese Participants
78 participantsStarted 2026-06
Plain-language summary
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions;
* Males or females;
* Body mass index (BMI) between 27.0 and 40.0 kg/m2, inclusive;
* Male subjects are not allowed to donate sperm, and female subjects are not allowed to donate eggs from the time the ICF is signed until at least 3 months after the last follow-up.
Exclusion Criteria:
* Obesity attributable, in the investigator's opinion, to medication use, endocrinologic or monogenic disorders;
* Having a significant medical history or clinical manifestations related to any allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine (other than overweight or obesity), or psychiatric conditions that are severe or unstable (determined by the investigator or medically qualified designee);
* Evidence of active cancer within 2 years prior to screening (non-melanoma skin cancer, localized prostate cancer treated with curative intent, or other in situ carcinoma that does not require systemic therapy and is considered cured for at least 1 year is allowed);
* Acute febrile illness within 7 days prior to randomization or evidence of active infection
* Any major surgery within 3 months prior to screening or plan to have any major surgery during the study;
* History of clinically significant hypersensitivity, intolerance, or allergy to any oligonucleotide or GalNAc as determin…
What they're measuring
1
Incidence of treatment-emergent adverse events (TEAEs)